Introduction {#tca12875-sec-0005}
============

The manifold composition of stromal cells, immune cells, and molecular factors in the microenvironment of non‐small cell lung cancer (NSCLC) plays a significant role in supporting initiation, progression, and metastasis.[1](#tca12875-bib-0001){ref-type="ref"}, [2](#tca12875-bib-0002){ref-type="ref"}, [3](#tca12875-bib-0003){ref-type="ref"} VEGF, one of the crucial molecular factors stimulating angiogenesis and extracellular matrix remodeling, has been shown to take a central part in the development of a wide array of solid cancer types.[1](#tca12875-bib-0001){ref-type="ref"}, [4](#tca12875-bib-0004){ref-type="ref"}, [5](#tca12875-bib-0005){ref-type="ref"} Recently, with increasing knowledge of the effects of inducing inhibitory checkpoint proteins and of promoting the accumulation of myeloid‐derived suppressor and T‐regulatory cells in tumor milieu, the immunosuppressive property of VEGF has also been recognized.[6](#tca12875-bib-0006){ref-type="ref"}, [7](#tca12875-bib-0007){ref-type="ref"}, [8](#tca12875-bib-0008){ref-type="ref"}

Given the involvement of VEGF in these common features of cancer, the VEFG‐blocking agent bevacizumab has shown clinical efficacy for most non‐squamous (nonsq)‐NSCLC patients, regardless of the presence or absence of an *EGFR* driving mutation.[9](#tca12875-bib-0009){ref-type="ref"}, [10](#tca12875-bib-0010){ref-type="ref"}, [11](#tca12875-bib-0011){ref-type="ref"} However, no unique biomarkers or specific clinical profiles of fair consensus have been identified to distinguish the subgroup of patients that can particularly benefit from the VEFG‐blocking agent. In the JO25567 trial comparing erlotinib plus bevacizumab to erlotinib alone, each clinical study subgroup showed a relative risk reduction; therefore treatment to subgroup interaction was not evaluable, although patients with malignant pericardial or pleural effusion appeared to attain some additional efficacy with the add‐on of bevacizumab.[11](#tca12875-bib-0011){ref-type="ref"}

While using a combination of the VEFG‐blocking agent with either chemotherapy or an EGFR‐tyrosine kinase inhibitor (TKI) for the treatment of nonsq‐NSCLC is clinically evident, the treatment length and timing of administering such an agent are less well understood. In view of the angiogenic and immunosuppressive role that VEGF plays in the tumor microenvironment, a continuous VEGF‐blocking strategy may provide clinical benefit to patients. Previous studies have addressed this issue focusing on maintenance treatment[12](#tca12875-bib-0012){ref-type="ref"}, [13](#tca12875-bib-0013){ref-type="ref"}, [14](#tca12875-bib-0014){ref-type="ref"} or treatment beyond progression[15](#tca12875-bib-0015){ref-type="ref"} rather than dealing with the actual number of treatment cycles used. Nadler *et al*. retrospectively analyzed 403 patients receiving first‐line chemotherapy plus bevacizumab and reported that those who subsequently underwent bevacizumab maintenance until progression had significantly better overall survival (OS) and progression‐free survival (PFS) compared to those who did not.[13](#tca12875-bib-0013){ref-type="ref"} On the other hand, a randomized phase IIb trial conducted by Takeda *et al*. showed that administering bevacizumab treatment beyond progression yielded a PFS benefit and also a trend of OS benefit, suggesting the possible prognostic advantage of keeping VEGF inhibited.[15](#tca12875-bib-0015){ref-type="ref"} Despite differences in the populations between the two studies, a similar benefit of continuous VEGF‐blocking was noted, which thereby raises the question of the number of bevacizumab treatment cycles that would provide most benefit.

Apart from continuous VEGF blockade, the timing of VEGF inhibition, in terms of commencing bevacizumab at first‐line or beyond, remains an issue. Herbst *et al*. performed two second‐line studies. One showed that in patients who received the VEGF‐blocking strategy later still gained a trend of PFS and OS benefit compared to patients not treated with VEGR blockade,[16](#tca12875-bib-0016){ref-type="ref"} whereas the other study showed a PFS but not an OS benefit.[17](#tca12875-bib-0017){ref-type="ref"} Recently, better efficacy has also been reported in third‐line or further settings.[18](#tca12875-bib-0018){ref-type="ref"} However, whether the introduction of a VEGF‐blocking strategy at first‐line or later affects the survival outcome is not yet known.

We analyzed a cohort of advanced *EGFR*‐mutant and *EGFR*‐wild type nonsq‐NSCLC patients who received bevacizumab in combination with chemotherapy or EGFR‐TKIs at different lines and varying treatment cycles. The number of treatment cycles and the timing of starting bevacizumab were analyzed to determine an influence on survival outcome. This influence was also analyzed by clinical subgroups.

Methods {#tca12875-sec-0006}
=======

Patients {#tca12875-sec-0007}
--------

From January 2011 to November 2017, the data of 132 patients with advanced or metastatic NSCLC who received at least one cycle of bevacizumab‐based treatment (7.5 mg/kg, every 3 weeks) at Chang Gung Memorial Hospital were retrospectively reviewed. Twelve patients were excluded because of a short follow‐up duration (\< 4 weeks) after bevacizumab‐based treatment and five were excluded because of a diagnosis of squamous cell carcinoma. The remaining 115 patients were eligible for the analysis (Fig [1](#tca12875-fig-0001){ref-type="fig"}a). Bevacizumab was initially combined with either chemotherapy or EGFR‐TKIs, and the physician in charge decided the treatment strategy, namely maintenance, treatment beyond progression, and line of treatment. The clinical profiles and the toxicities noted during bevacizumab‐based treatment were systemically reviewed. OS was defined as the interval between the date of commencing non‐curable intent treatment and the date of either death or the last follow‐up. The treatment response, defined as complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD) was evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.[19](#tca12875-bib-0019){ref-type="ref"} Toxicity was graded according to National Cancer Institute Common Toxicity Criteria, version 3.0.[20](#tca12875-bib-0020){ref-type="ref"} The ethics committee of Chang Gung Memorial Hospital, Linkou, Taiwan, approved the study.

![(**a**) Flow chart of the study population. (**b**) Kaplan--Meier curve with 95% confidence interval (red shade) of the overall survival of the study population. NSCLC, non‐small cell lung cancer.](TCA-9-1648-g001){#tca12875-fig-0001}

Statistical analysis {#tca12875-sec-0008}
--------------------

A Mann--Whitney *U* test was used to determine the statistical significance between two groups of continuous variables and Fisher\'s exact tests were used for categorical variables. The median follow‐up duration was reported using the reverse Kaplan--Meier method. The number of cycles of bevacizumab treatment, which carried an intrinsic guarantee‐time bias,[21](#tca12875-bib-0021){ref-type="ref"} was treated as time‐dependent covariate, where R package *survival* (R Foundation for Statistical Computing, Vienna, Austria) was used to transform the covariate coded by the time of change in a timeframe fashion. R package *survival* was also used for the extended Kaplan--Meier method to estimate the survival curves[22](#tca12875-bib-0022){ref-type="ref"} and the hazard ratio (HR) was analyzed using the Cox regression model, where the proportional hazard assumption was confirmed for each covariate beforehand. All reported *P* values were two sided, with *P* \< 0.05 considered statistically significant. All data were analyzed using SPSS version 10.1 (SPSS Inc., Chicago, IL, USA).

Results {#tca12875-sec-0009}
=======

Baseline patient characteristics {#tca12875-sec-0010}
--------------------------------

Among the 115 patients, 53 (46.1%) were male, 29 (25.2%) were smokers or ex‐smokers, and 67 (58.3%) had *EGFR*‐mutated nonsq‐NSCLC (Table [1](#tca12875-tbl-0001){ref-type="table"}). Eighty‐four (73.0%) patients were at Eastern Cooperative Oncology Group performance status (ECOG PS) 0--1 when they underwent bevacizumab‐based treatment and the median number of bevacizumab cycles was five (range: 1--31). Eighty‐six (74.8%) patients initially received bevacizumab in combination with chemotherapy and 29 (25.2%) in combination with EGFR‐TKIs. Bevacizumab was used as first‐line treatment in 47 (40.9%) patients and as second‐line or later settings in 68 (59.1%). The adverse grade 3 events noted during bevacizumab‐based treatment included: bleeding in 11 (9.6%), proteinuria in 4 (3.5%), venous thrombosis in 3 (2.6%), and hypertension in 23 (20.0%) patients. Outcomes of the bevacizumab‐based combination were: PR in 42 (36.5%), SD in 20 (17.3%), and PD in 53 (46.0%) patients. The median OS was 26.6 months (Fig [1](#tca12875-fig-0001){ref-type="fig"}b) and the median follow‐up duration was 40.3 months.

###### 

Clinical characteristics of study subjects

  Variable, N (%)                                           Overall population (*n* = 115)
  -------------------------------------------------------- --------------------------------
  Age, median (range), year                                          58 (26--82)
  Gender (male)                                                       53 (46.0)
  Smoker/ex‐smoker                                                    29 (25.2)
  ECOG PS                                                  
  0, 1                                                                84 (73.0)
  ≥ 2                                                                 31 (27.0)
  Staging                                                  
  III                                                                  11 (9.6)
  IV                                                                  104 (90.4)
  *EGFR* status                                            
  Mutation                                                            67 (58.3)
  Wild type                                                           36 (31.3)
  Unknown                                                             12 (10.4)
  Regimen combination                                      
  Chemotherapy                                                        86 (74.8)
  EGFR‐TKI                                                            29 (25.2)
  Comorbidity                                              
  Chronic liver disease                                                9 (7.8)
  Chronic kidney disease                                               4 (3.5)
  Adverse effects[†](#tca12875-note-0002){ref-type="fn"}   
  Proteinuria                                                          4 (3.4)
  Hypertension                                                        23 (20.0)
  Bleeding                                                             11 (9.6)
  Venous thrombosis                                                    3 (2.6)
  Treatment response                                       
  Partial response                                                    42 (36.5)
  Stable disease                                                      20 (17.3)
  Progression disease                                                 53 (46.0)

Grade 3.

ECOG PS, Eastern Cooperative Oncology Group performance status; TKI, tyrosine kinase inhibitor.

Number of treatment cycles and line of bevacizumab {#tca12875-sec-0011}
--------------------------------------------------

To determine whether the number of cycles and the timing of bevacizumab administration had an influence on survival outcomes, patients were grouped by treatment strategies: the number of cycles (≥ 5 vs. 1--4) and the line (first‐line vs. second or later) (Table [2](#tca12875-tbl-0002){ref-type="table"}). Patients administered ≥ 5 cycles of bevacizumab were observed to have significantly better ECOG PS (PS 0--1, 93.2% vs. 60.6%; *P* \< 0.001), were younger (55 \[46--61\] vs. 59 \[52--69\]; *P* = 0.043), and had a higher response rate (59.1% vs. 22.5%; *P* \< 0.001) compared to patients administered 1--4 cycles. Patients who received bevacizumab in the first‐line setting also had a significantly better ECOG PS (PS 0--1, 87.2% vs. 63.2%; *P* = 0.002), were more often male (59.6% vs. 36.8%; *P* = 0.026), with wild‐type *EGFR* (48.9% vs. 19.1%; *P* = 0.001), and had a higher response rate (48.9% vs. 27.9%; *P* = 0.030) compared to patients administered bevacizumab in the second or later line setting.

###### 

Clinical characteristics of the patients stratified by the number of treatment cycles and the line of bevacizumab

  Variables, N (%)                                          Treatment cycle   Treatment line                                         
  -------------------------------------------------------- ----------------- ---------------- ---------- ------------- ------------- -------
  Age, median (range), year                                   55 (46--61)      59 (52--69)      0.043     57 (49--64)   59 (51--65)   0.914
  Gender (male)                                                19 (43.1)        34 (47.9)       0.765      28 (59.6)     25 (36.8)    0.026
  Smoker/ex‐smoker                                             11 (25.0)        18 (25.4)       0.858      16 (34.0)     13 (19.1)    0.111
  ECOG PS                                                                                                                            
  0, 1                                                         41 (93.2)        43 (60.6)      \< 0.001    41 (87.2)     43 (63.2)    0.008
  ≥ 2                                                           3 (6.8)         28 (39.4)                  6 (12.8)      25 (36.8)   
  Staging                                                                                                                            
  III                                                           4 (8.7)          7 (9.9)        0.909      6 (12.8)       5 (7.4)     0.517
  IV                                                           42 (91.3)        64 (90.1)                  41 (87.2)     63 (92.3)   
  *EFGR* status                                                                                                                      
  Mutation                                                     21 (47.7)        46 (64.7)       0.096      21 (44.7)     46 (67.6)    0.003
  Wild type                                                    19 (43.2)        17 (23.9)                  23 (48.9)     13 (19.1)   
  Unknown                                                       4 (9.0)          8 (11.2)                   3 (6.4)      9 (13.2)    
  Regimen of combination                                                                                                             
  Chemotherapy                                                 35 (79.5)        51 (71.8)       0.481      35 (74.5)     51 (75.0)    0.878
  EGFR‐TKI                                                     9 (20.5)         20 (21.2)                  12 (25.5)     17 (25.0)   
  Comorbidity                                                                                                                        
  Chronic liver disease                                         3 (6.8)          6 (8.5)        1.000       2 (4.3)      7 (10.3)     0.405
  Chronic kidney disease                                        2 (4.5)          2 (2.8)        1.000       1 (2.1)       3 (4.4)     0.889
  Adverse effects[†](#tca12875-note-0004){ref-type="fn"}                                                                             
  Proteinuria                                                   1 (2.2)          3 (4.2)        0.133       2 (4.3)       2 (2.9)     0.153
  Hypertension                                                 9 (20.5)         14 (19.7)                  9 (19.1)      14 (20.6)   
  Bleeding (Grade 3)                                            2 (4.5)          9 (12.7)                   2 (4.3)      9 (13.2)    
  Venous thrombosis                                             3 (6.8)             0                       3 (6.3)          0       
  Treatment response                                                                                                                 
  Partial response                                             26 (59.1)        16 (22.5)      \< 0.001    23 (48.9)     19 (27.9)    0.004
  Stable disease                                               12 (27.3)         8 (11.3)                  11 (23.4)     9 (13.2)    
  Progressive disease                                          6 (13.6)         47 (66.2)                  13 (27.7)     40 (58.8)   

Grade 3.

ECOG PS, Eastern Cooperative Oncology Group performance status; TKI, tyrosine kinase inhibitor.

Analysis of predictors of survival outcome {#tca12875-sec-0012}
------------------------------------------

A Cox regression model was subsequently analyzed to determine the predictors of OS (Table [3](#tca12875-tbl-0003){ref-type="table"}). In univariate analysis, neither age (HR 1.02, 95% confidence interval \[CI\] 0.99--1.03; *P* = 0.502) nor male gender (HR 1.20, 95% CI 0.75--1.93; *P* = 0.453) had an impact on OS, whereas ECOG PS (PS ≥ 2, HR 4.09, 95% CI 2.49--6.71; *P* \< 0.001) and bleeding events during bevacizumab treatment (HR 2.38, 95% CI 1.43--3.98; *P* = 0.001) were significant predictive factors of poor OS. Wild‐type *EGFR* (HR 1.64, 95% CI 0.95--2.83; *P* = 0.075) and brain metastasis in patients administered bevacizumab (HR 1.62, 95% CI 0.98--2.67; *P* = 0.058) also presented a trend as negative predictors of OS. Neither ≥ 5 cycles of bevacizumab treatment (HR 0.96, 95% CI 0.53--1.72; *P* = 0.884) nor the first‐line use of bevacizumab (HR 1.16, 95% CI 0.70--1.92; *P* = 0.573) was predictive of OS. In multivariate analysis, ECOG PS (PS ≥ 2, HR 4.78, 95% CI 2.68--8.51; *P* \< 0.001), wild‐type *EGFR* (HR 2.61, 95% CI 1.45--4.70; *P* = 0.001), and bleeding events during bevacizumab treatment (HR 3.63, 95% CI 1.77--7.45; *P* \< 0.001) remained predictive of poor OS.

###### 

Cox regression analysis of overall survival

  Variables                           Univariate       Multivariate                      
  ------------------------------- ------------------- -------------- ------------------- ----------
  Age                              1.02 (0.99--1.03)      0.502              ---            ---
  Gender (Male)                    1.20 (0.75--1.93)      0.453              ---            ---
  Smoker                           0.94 (0.53--1.68)      0.833              ---            ---
  Brain metastasis                 1.62 (0.98--2.67)      0.058       1.58 (0.89--2.81)    0.117
  ECOG PS ≥ 2                      4.09 (2.49--6.71)     \< 0.001     3.95 (2.22--7.01)   \< 0.001
  Wild‐type *EGFR*                 1.64 (0.95--2.83)      0.075       2.96 (1.61--5.44)    0.001
  First‐line use of bevacizumab    1.16 (0.70--1.92)      0.575              ---            ---
  Cycles of bevacizumab ≥ 5        0.96 (0.53--1.71)      0.883              ---            ---
  Bleeding event                   2.38 (1.43--3.98)      0.001       2.27 (1.25--4.11)    0.007

CI, confidence interval; HR, hazard ratio.

Subgroup analysis of the treatment cycle and line of bevacizumab {#tca12875-sec-0013}
----------------------------------------------------------------

As the number of treatment cycles and line of bevacizumab did not influence the survival outcome in the overall population, we analyzed whether there was any influence in clinical subgroups. A forest plot showed that the administration of ≥ 5 cycles of bevacizumab was associated with a significant survival benefit in the wild‐type *EGFR* subgroup compared to 1--4 cycles (HR 0.28, 95% CI 0.08--0.98; *P* = 0.044) (Fig [2](#tca12875-fig-0002){ref-type="fig"}a), although there was no significant difference in the clinical profiles between these groups (Table [S1](#tca12875-supitem-0001){ref-type="supplementary-material"}, Supporting Information). No beneficial effect of ≥ 5 treatment cycles was observed in the *EGFR* mutation subgroup (HR 1.12, 95% CI 0.52--2.42; *P* = 0.777); thus a significant association between the number of cycles and *EGFR* status was noted (*P* = 0.046). Regarding the treatment line, a forest plot showed that first‐line use of bevacizumab was not associated with a significant survival benefit compared to second or later line use, regardless of *EGFR* mutation status (Fig [2](#tca12875-fig-0002){ref-type="fig"}b); however, a trend of better survival was observed in the wild‐type *EGFR* subgroup (HR 0.48, 95% CI 0.20--1.17; *P* = 0.105). In addition, while significantly poorer survival was associated with first‐line bevacizumab use in the PS 0--1 subgroup (Fig [2](#tca12875-fig-0002){ref-type="fig"}b), a biased wild‐type *EGFR* disposition toward first‐line bevacizumab was noted in this subgroup, which invalidated the finding (Table [S2](#tca12875-supitem-0001){ref-type="supplementary-material"}, Supporting Information).

![Forest plot of treatment to subgroup analysis. (**a**) Number of bevacizumab treatment cycles: ≥ 5 versus 1--4 cycles. (**b**) First‐line versus second or later lines of bevacizumab. CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio; NSCLC, non‐small cell lung cancer.](TCA-9-1648-g007){#tca12875-fig-0002}

Survival estimate of treatment by *EGFR* mutation status {#tca12875-sec-0014}
--------------------------------------------------------

As subgroup analysis revealed an association between bevacizumab treatment strategy and *EGFR* status, the Kaplan--Meier estimator was subsequently analyzed. In wild‐type *EGFR* patients, the median OS was significantly longer in patients treated with ≥ 5 cycles compared to 1--4 cycles (22.8 vs. 13.5 months; *P* = 0.048) (Fig [3](#tca12875-fig-0003){ref-type="fig"}a), whereas the median OS of the first‐line treatment group was numerically but not statistically longer than the second or later line group (22.8 vs. 12.9 months; *P* = 0.097) (Fig [3](#tca12875-fig-0003){ref-type="fig"}c). In the patients with *EGFR* mutations, the median OS was similar regardless of the number of cycles (28.4 vs. 29.4 months; *P* = 0.777) (Fig [3](#tca12875-fig-0003){ref-type="fig"}b) or the treatment line (30.0 vs. 29.2 months; *P* = 0.771) (Fig [3](#tca12875-fig-0003){ref-type="fig"}d).

![Kaplan--Meier curve analysis of *EGFR* status (column side) to bevacizumab treatment (row side). \**P* value of Cox‐regression model; \# *P* value of log‐rank test. (**a,b**) Number of treatment cycles: (![](TCA-9-1648-g006.jpg "image")) 1--4, (![](TCA-9-1648-g004.jpg "image")) ≥ 5. (**c,d**) Treatment line: (![](TCA-9-1648-g002.jpg "image")) second or later line, (![](TCA-9-1648-g005.jpg "image")) first‐line.](TCA-9-1648-g003){#tca12875-fig-0003}

Discussion {#tca12875-sec-0015}
==========

This study evaluated the predictive factors of OS in a cohort of bevacizumab‐treated nonsq‐NSCLC patients with a disposition of wild type and mutant *EGFR* at an approximate 1:2 ratio. In addition to the commonly recognized negative OS predictors (ECOG PS ≥ 2 and wild‐type *EGFR*), bleeding events during bevacizumab treatment were also identified as negatively associated with OS. Although treatment with ≥ 5 bevacizumab cycles was not predictive of OS in the overall study population, it was associated with positive OS in *EGFR* wild‐type patients. This result indicates that treatment with ≥ 5 cycles of bevacizumab yields a higher OS benefit/risk reduction in wild‐type *EGFR* patients, thus a differential OS impact between the number of bevacizumab cycles and *EGFR* mutation status was identified.

Although previous studies have shown the efficacy of VEGF blockade using bevacizumab in both *EGFR*‐mutant and *EGFR*‐wild type nonsq‐NSCLC patients, our results suggest that the extent of the beneficial effect from prolonged and early VEGF blockade may be different between these two molecular phenotypes. One of the possible reasons underlying this distinction can be linked to differences in the tumor microenvironment. Recent studies of immune checkpoint inhibitors showed that tumors with *EGFR* sensitizing mutations had significantly lower response rates compared to wild‐type *EGFR* tumors,[23](#tca12875-bib-0023){ref-type="ref"} as a result of less abundant immune cell infiltration and weaker immunogenicity in the *EGFR*‐mutant tumor microenvironment.[24](#tca12875-bib-0024){ref-type="ref"} The lower infiltration of immune cells, including CD8 T and CD4 T regulatory and myeloid‐derived suppressor cells, indicates a reduction in the number of target cells that VEGF can engage to augment immunosuppression through the VEGF/VEFG‐R2 signaling pathway,[6](#tca12875-bib-0006){ref-type="ref"}, [7](#tca12875-bib-0007){ref-type="ref"}, [25](#tca12875-bib-0025){ref-type="ref"} thereby diminishing the role VEGF plays in this microenvironment context and leading to moderation of the beneficial effect of bevacizumab. In line with this, treatments using VEGF and VEGFR blocking agents in combination with checkpoint protein inhibitors, mainly for non‐driving mutation NSCLCs, are being actively investigated with encouraging results.[26](#tca12875-bib-0026){ref-type="ref"}, [27](#tca12875-bib-0027){ref-type="ref"}, [28](#tca12875-bib-0028){ref-type="ref"}

The relatively modest benefit of bevacizumab treatment in *EGFR*‐mutant tumors was also shown in the JO25567 trial,[29](#tca12875-bib-0029){ref-type="ref"} where the addition of bevacizumab to erlotinib did not decrease the risk of death as opposed to erlotinib alone (HR 0.81, 95% CI 0.53--1.23; *P* = 0.327) and yielded similar median OS (47.0 vs. 47.4 months) in the two groups, although the combination of bevacizumab plus erlotinib had previously shown significantly better efficacy.[11](#tca12875-bib-0011){ref-type="ref"} This result also explains why the prolonged and early VEGF‐blocking strategy did not yield a positive effect on OS in our study; as *EGFR*‐mutant nonsq‐NSCLC patients accounted for approximately 60% of our study population, the positive effect on OS of the wild‐type *EGFR* subjects was thus diluted.

With regard to using a VEGF‐blocking strategy for wild‐type *EGFR* tumors, our findings suggest that a prolonged rather than an early VEGF blockade was more beneficial. A recent study of the combination of bevacizumab to salvage treatment at third‐line or beyond showed improved efficacy compared to the salvage treatment alone, confirming that the clinical benefit of a VEGF‐blocking strategy is preserved, even when introduced at later lines.[18](#tca12875-bib-0018){ref-type="ref"} On the other hand, Takeda *et al*. revealed the significance of prolonged VEGF blockade, reporting that failure of prior treatment containing bevacizumab does not prevent continuous use in further lines of treatment as VEGF may still play a role.[15](#tca12875-bib-0015){ref-type="ref"}

The present study further identified that bleeding during bevacizumab treatment was a negative factor for OS. No fatal or central nervous system bleeding was observed, although the frequency of brain metastasis (55.7%) tended to be higher in our study population. The 11 (9.6%) patients who experienced bleeding events (9 \[81.8%\] from the gastrointestinal tract, 2 \[18.2%\] from hemoptysis) discontinued bevacizumab. The overall rate of bleeding events tended to be higher than in previous reports,[30](#tca12875-bib-0030){ref-type="ref"}, [31](#tca12875-bib-0031){ref-type="ref"} but whether this is associated with the underlying comorbidity of chronic liver and kidney disease in the study population (11.3%) requires further evaluation.

A limitation of the present study was the inherent bias as a result of the retrospective and heterogeneous nature of the study population, such as the molecular profile of *EGFR*. It was difficult to determine the differential responses to treatment associated with different tumor molecular phenotypes from previous studies because they included large numbers of *EGFR* mutant or wild‐type patients. However, at the expense of a homogeneous *EGFR* mutation profile, the present study revealed a differential OS impact between the number of bevacizumab cycles and *EGFR* mutation status.

In conclusion, prolonged and early VEGF blockade is an effective therapeutic approach for nonsq‐NSCLC, and caution must be taken in the event of bleeding. Patients with wild‐type *EGFR* tumors may particularly benefit from this treatment strategy.

Disclosure {#tca12875-sec-0016}
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**Table S1.** Clinical characteristics of wild‐type *EGFR* subjects stratified by the number of treatment cycles of bevacizumab.

**Table S2.** Clinical characteristics of Eastern Cooperative Oncology Group performance status (ECOG PS) 0--1 of subjects stratified by the bevacizumab treatment line.

###### 

Click here for additional data file.
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